Vakaramoko Diaby to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Vakaramoko Diaby has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.143
-
Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
Score: 0.143